Analysis of 20 years of FDA adverse event data found that GLP-1 drugs (semaglutide, dulaglutide, liraglutide) were associated with 76-84% lower odds of multiple sclerosis reports, suggesting potential for drug repurposing.
76-84% lower MS oddsGLP-1 receptor agonists showed dramatically reduced MS reporting odds in 20 years of FDA adverse event data
What the researchers found
GLP-1 receptor agonists showed significant inverse associations with MS: semaglutide ROR 0.238, dulaglutide ROR 0.165, liraglutide ROR 0.161 (all p<0.05), while non-GLP-1 weight-loss drugs showed no inverse association.
Why it matters
Multiple sclerosis affects millions worldwide and current treatments are immunosuppressive with significant side effects. If GLP-1 drugs have genuine protective effects against MS, they could represent a safer, more tolerable treatment option — especially since they're already widely used and well-understood.
The numbers in context
Analysis of FDA AERS database. Obesity linked to MS through pro-inflammatory adipokines like leptin.
How the study worked
Disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database from Q4 2003 to Q2 2023. Inverse association defined as upper limit of 95% CI for reporting odds ratio <1.
Who was studied
FDA AERS database analysis of weight loss medication users
What this study cannot tell us
FAERS database analysis cannot establish causation — only association. Reporting biases are inherent (e.g., diabetic patients may be less likely to also have MS diagnosed, or MS patients may avoid GLP-1 drugs). Confounders like age, sex, and comorbidities could not be fully controlled.
How to read the evidence
Preliminary evidence from a pharmacoepidemiological database analysis. Generates a hypothesis but cannot establish causation. Needs validation through prospective clinical studies.
When this study was published
Published in 2024. Represents an early signal in an emerging area of GLP-1 drug repurposing research.
The bigger picture
This adds to the growing list of potential non-metabolic benefits of GLP-1 drugs, which now includes cardiovascular protection, kidney protection, and possible neuroprotective effects. The anti-inflammatory properties of GLP-1 receptor agonists provide a biologically plausible mechanism for MS protection.
Questions still open
- Would a prospective clinical trial of GLP-1 drugs in MS patients confirm this protective signal?
- Is the anti-inflammatory mechanism of GLP-1 drugs sufficient to explain this inverse association?
- Could GLP-1 drugs prevent MS in high-risk populations, such as those with obesity during adolescence?
Common questions
Does this mean GLP-1 drugs can treat or prevent multiple sclerosis?
Why might GLP-1 drugs affect multiple sclerosis?
Read the original research
Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.
Therapeutic advances in neurological disorders, 17, 17562864241241383
Citation
Shirani, Afsaneh; Cross, Anne H; Stuve, Olaf. (2024). Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.. Therapeutic advances in neurological disorders, 17, 17562864241241383. https://doi.org/10.1177/17562864241241383